FDA Could Face Extended Leadership Vacancy
FDA could remain without a permanent commissioner for an extended period following the 11/17 withdrawal of Heidi Overton's nomination, complicating the agency's efforts to secure congressional support for user-fee reauthorization and other regulatory reforms.
According to an 11/19 Semafor report, former FDA officials expect the agency could be led by a succession of acting commissioners over the next two years as Democrats assume control of the Senate. The report follows FDA Webview's 11/18 story in which Senate HELP Committee Chairman Bill Cassidy (R-LA) disputed the White House's explanation for withdrawing Overton's nomination, saying she had sufficient support for confirmation.
Semafor identifies former acting commissioner Sara Brenner and CBER director Karim Mikhail as possible temporary leaders. The White House has also reportedly considered outgoing Sen. Roger Marshall (R-KS) as a replacement nominee.
The leadership uncertainty comes as Congress prepares to reauthorize FDA's industry user-fee programs, which provide roughly half the agency's funding. Sen. Bernie Sanders (I-VT), who is expected to chair the Senate HELP Committee next year, told reporters he shares concerns about potential conflicts of interest arising from industry financing of FDA regulation.
“If we’re going to regulate a very, very significant industry, it might be a good idea not to have the industry paying for their regulation,” Sanders said.
Semafor reports that failure to renew the programs would require Congress to replace more than $3.5 billion in industry funding. The reauthorization process could also become a vehicle for proposals to expand FDA's authority over mandatory drug recalls and pharmaceutical supply-chain information, among other potential reforms.